JP2020508066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508066A5 JP2020508066A5 JP2019546141A JP2019546141A JP2020508066A5 JP 2020508066 A5 JP2020508066 A5 JP 2020508066A5 JP 2019546141 A JP2019546141 A JP 2019546141A JP 2019546141 A JP2019546141 A JP 2019546141A JP 2020508066 A5 JP2020508066 A5 JP 2020508066A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- cells
- domain
- heterologous chimeric
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 104
- 108020001507 fusion proteins Proteins 0.000 claims description 104
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 25
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 108010042215 OX40 Ligand Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 210000000225 synapse Anatomy 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 230000037453 T cell priming Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004941 influx Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 101710102027 V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 claims 13
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 claims 13
- 102000004473 OX40 Ligand Human genes 0.000 claims 9
- 230000002045 lasting effect Effects 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 10
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- -1 LIGHT Proteins 0.000 description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000050320 human TNFRSF4 Human genes 0.000 description 1
- 102000057058 human VSIR Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023036738A JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463999P | 2017-02-27 | 2017-02-27 | |
| US62/463,999 | 2017-02-27 | ||
| PCT/US2018/020038 WO2018157163A1 (en) | 2017-02-27 | 2018-02-27 | Vsig8-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023036738A Division JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508066A JP2020508066A (ja) | 2020-03-19 |
| JP2020508066A5 true JP2020508066A5 (https=) | 2021-04-08 |
| JP7244428B2 JP7244428B2 (ja) | 2023-03-22 |
Family
ID=63253418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546141A Active JP7244428B2 (ja) | 2017-02-27 | 2018-02-27 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2023036738A Pending JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A Withdrawn JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023036738A Pending JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A Withdrawn JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11192933B2 (https=) |
| EP (2) | EP4249503A3 (https=) |
| JP (3) | JP7244428B2 (https=) |
| CN (2) | CN118184797A (https=) |
| AU (1) | AU2018224852B2 (https=) |
| CA (1) | CA3054130A1 (https=) |
| IL (1) | IL268170A (https=) |
| WO (1) | WO2018157163A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3930851A4 (en) * | 2019-02-28 | 2023-03-29 | Shattuck Labs, Inc. | COMBINATION THERAPIES |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| EP4377334A4 (en) * | 2021-07-26 | 2025-06-18 | Kite Pharma, Inc. | DNVSIG3 AND DNVSIG8 RECEIVERS AND METHODS OF USE THEREOF |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| EP0745121B1 (en) | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DK0770397T3 (da) | 1995-10-18 | 2004-08-09 | Akzo Nobel Nv | Newcastle disease viruskombinationsvaccine |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| IL150571A0 (en) | 2000-01-03 | 2003-02-12 | Tr Associates L L C | Novel chimeric proteins and methods for using the same |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| CA2729351C (en) | 2008-06-30 | 2017-01-24 | University Of Pennsylvania | Fn14/trail fusion proteins |
| NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| CA2755198A1 (en) | 2009-03-13 | 2010-09-16 | Mark L. Tykocinski | Ox40/trail fusion proteins |
| CA2769822C (en) * | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| MX374075B (es) | 2010-03-26 | 2025-03-05 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| US20180237525A9 (en) | 2010-03-26 | 2018-08-23 | Randolph J. Noelle | VISTA Agonist and Methods of Use |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| CN104271150A (zh) * | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| WO2013119202A1 (en) | 2012-02-06 | 2013-08-15 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using ox40 agonists |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| PT2850106T (pt) | 2012-05-18 | 2022-07-18 | Aptevo Res & Development Llc | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
| EP3202419A1 (en) * | 2012-06-06 | 2017-08-09 | OncoMed Pharmaceuticals, Inc. | Pvrig binding agents that modulate the hippo pathway and uses thereof |
| JP6285923B2 (ja) | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9381244B2 (en) | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2014106839A1 (en) | 2013-01-01 | 2014-07-10 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| WO2014121085A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| EP3148573A4 (en) | 2014-05-29 | 2017-11-15 | Medimmune, LLC | Ox40l fusion proteins and uses thereof |
| EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| PL3180363T3 (pl) | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CA2969730A1 (en) * | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| WO2018027042A1 (en) | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
-
2018
- 2018-02-27 EP EP23176998.5A patent/EP4249503A3/en active Pending
- 2018-02-27 JP JP2019546141A patent/JP7244428B2/ja active Active
- 2018-02-27 CA CA3054130A patent/CA3054130A1/en active Pending
- 2018-02-27 US US16/484,854 patent/US11192933B2/en active Active
- 2018-02-27 AU AU2018224852A patent/AU2018224852B2/en not_active Expired - Fee Related
- 2018-02-27 CN CN202410306323.7A patent/CN118184797A/zh active Pending
- 2018-02-27 WO PCT/US2018/020038 patent/WO2018157163A1/en not_active Ceased
- 2018-02-27 CN CN201880010430.8A patent/CN110290798B/zh active Active
- 2018-02-27 EP EP18757138.5A patent/EP3585410B9/en active Active
-
2019
- 2019-07-18 IL IL268170A patent/IL268170A/en unknown
- 2019-10-28 US US16/665,803 patent/US11192934B2/en active Active
-
2021
- 2021-11-01 US US17/516,006 patent/US11834488B2/en active Active
-
2023
- 2023-03-09 JP JP2023036738A patent/JP2023071979A/ja active Pending
- 2023-10-24 US US18/492,982 patent/US20240067698A1/en not_active Abandoned
-
2025
- 2025-02-10 JP JP2025020276A patent/JP2025065443A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508068A5 (https=) | ||
| JP2020508063A5 (https=) | ||
| JP2020508329A5 (https=) | ||
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| US10329338B2 (en) | Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon | |
| CN107082812B (zh) | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 | |
| CN104114233B (zh) | 转换共刺激受体 | |
| WO2019201161A1 (zh) | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 | |
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| JP2018529363A5 (https=) | ||
| JP2020510653A (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２、ｃｅａまたはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| CN110114368A (zh) | 靶向突变干扰素-γ及其用途 | |
| KR20190115469A (ko) | Bcma, nkg2d 및 cd16에 결합하는 단백질 | |
| JP2020508066A5 (https=) | ||
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| JP2021520229A (ja) | 抗ｇｕｃｙ２ｃキメラ抗原受容体の組成物および方法 | |
| WO2014124217A1 (en) | A selective high-affinity immune stimulatory reagent and uses thereof | |
| CN104284680A (zh) | 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物 | |
| CN109195988A (zh) | 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物 | |
| JP2022527643A (ja) | がん治療のための免疫療法 | |
| CN110475857B (zh) | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 | |
| KR20200068746A (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| JP2022512540A5 (https=) | ||
| KR20180119605A (ko) | ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer) | |
| KR20240137086A (ko) | Pd-1 작용제인 세포예정사 단백질 1에 대한 항체 |